Wasatch BioLabs Partners with Agilent to Advance Native-Read Targeted Sequencing Technology
核心洞察
Wasatch BioLabs (搜索) announced a co-marketing agreement with Agilent Technologies (搜索) to support adoption of its Direct Targeted Methylation Sequencing (dTMS) platform through 2027.
The collaboration integrates Agilent's SureSelect and Avida enrichment chemistries with WBL's Oxford Nanopore (搜索)-based workflow to enable precise targeting up to 1 Mb while preserving native DNA features.
Early adopters in oncology (搜索), neurology (搜索), rare disease (搜索), and prenatal research are already using dTMS to analyze structural variation, methylation patterns, and repeat expansions in unified assays.
Wasatch BioLabs (搜索) (WBL), a leader in native, long-read sequencing and epigenomic analysis, announced a co-marketing agreement with Agilent Technologies (搜索) to support adoption of its Direct Targeted Methylation Sequencing (dTMS) platform. The collaboration brings together Agilent's enrichment chemistries—SureSelect for genomic DNA and Avida for cell-free DNA—with WBL's proprietary Oxford Nanopore (搜索)-based native-read workflow, expanding access to scalable targeted multi-omic analysis for research use only (RUO) and clinical research studies.
Technology Integration Addresses Critical Sequencing Gaps
The SureSelect and Avida capabilities fill a critical gap in native-read sequencing by enabling precise, custom targeting up to 1 Mb while preserving native DNA features such as methylation and structural variants. By eliminating off-target sequencing, DNA damage from traditional bisulfite-based methods, and biases introduced by PCR amplification, researchers can capture true biology across large and short, customized genomic regions.
"Multi-omic biology is essential for understanding disease, but for broad adoption it has to be delivered in a way that scales," said Dean Lilley, Senior Director of Product Development at Wasatch BioLabs (搜索). "Our alignment with Agilent ensures that native-read targeted sequencing delivers integrated genetic and epigenetic insight, while establishing the consistency, reproducibility, and operational reliability required for high-throughput research and potential future clinical translation."
Early Clinical Applications Show Promise
Early adopters in oncology (搜索), neurology (搜索), rare disease (搜索), and prenatal research are already applying dTMS to resolve structural variation, allelic context, repeat expansions, and methylation patterns in a unified assay. These programs demonstrate how native-read targeted sequencing can support more comprehensive, mechanism-informed profiling across research areas such as liquid biopsy and large cohort studies.
The technology opens new doors for liquid biopsy and targeted genomic applications with cost-efficient, scalable, and highly precise approaches suitable for a broad array of research and screening applications.
Strategic Partnership Framework
"Partnering with Wasatch BioLabs (搜索) allows Agilent to deliver a next-generation experience for customers who need both innovation and operational flexibility," said Nina Green, vice president and general manager of Agilent's Clinical Diagnostics Division. "By integrating SureSelect and Avida enrichment with Wasatch's novel sequencing technology and robust send-out service model, we are enabling customers to access high-quality NGS data without workflow barriers."
Under the agreement, WBL and Agilent will jointly deliver scientific content, educational programming, and technology demonstrations through 2027. The organizations anticipate the collaboration will scale adoption of native-read targeted sequencing and accelerate the development of cost-efficient, relevant native-read assays.
Market Access and Future Development
The service will remain in early access through Q1 2026, with early adopters having the opportunity to shape future enhancements and gain first access to new capabilities. WBL welcomes additional partners interested in integrating the targeted sequencing assay into their research or development programs.
The collaboration accelerates adoption, improves turnaround times, and provides a powerful, innovation-led path to achieving high-confidence genomic insights at any scale, according to Green.